Glioma

In this video, Patrick Wen, MD, professor of neurology at Harvard Medical School and director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute, discusses promising new brain cancer treatments.

May is Brain Cancer Awareness Month.

The FDA approved dabrafenib with trametinib for children with previously untreated low-grade glioma who harbor BRAF V600E mutations and require systemic therapy.

Vorasidenib conferred statistically significant and clinically meaningful improvements in PFS and time to next intervention for patients with residual or recurrent IDH-mutant low-grade glioma, according to the agent’s manufacturer.

Tovorafenib monotherapy induced response among approximately two-thirds of patients with recurrent or progressive pediatric low-grade glioma, according to topline data released by the agent’s manufacturer.

September is Childhood Cancer Awareness Month.

The oncolytic adenovirus DNX-2401 appeared safe and feasible among a small cohort of pediatric patients with diffuse intrinsic pontine glioma, according to study results published in The New England Journal of Medicine.

Two-thirds of patients with relapsed pediatric low-grade glioma treated with tovorafenib responded to therapy, data released by the agent’s manufacturer showed.

The ideal strategy to treat cancer with cell therapy can vary greatly depending on tumor type.

CHICAGO — A combination of two targeted therapies significantly improved outcomes compared with standard care for children with BRAF V600 mutation-positive low-grade glioma, according to study results presented at ASCO Annual Meeting.